SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Davis J. E. | CEO and President, Director | 2026-09-01 | Open-market sell 10b5-1 | 10000 | $2.4M |
| PREVOZNIK MICHAEL E | SVP & General Counsel | 2026-08-28 | Option exercise 10b5-1 | 22677 | $2.5M |
| PREVOZNIK MICHAEL E | SVP & General Counsel | 2026-08-28 | Open-market sell 10b5-1 | 16010 | $3.9M |
| PREVOZNIK MICHAEL E | SVP & General Counsel | 2026-08-28 | Open-market sell 10b5-1 | 6237 | $1.5M |
| PREVOZNIK MICHAEL E | SVP & General Counsel | 2026-08-28 | Open-market sell 10b5-1 | 430 | $105K |
| PREVOZNIK MICHAEL E | SVP & General Counsel | 2026-08-28 | Gift 10b5-1 | 1000 | $0 |
| DELANEY MARK E | SVP & Chief Commercial Officer | 2026-07-28 | Open-market sell 10b5-1 | 1600 | $376K |
| CARTER ROBERT B | Director | 2026-07-22 | L | 11 | $2K |
| DELANEY MARK E | SVP & Chief Commercial Officer | 2026-07-22 | L | 34 | $7K |
| Gregg Vicky B | Director | 2026-07-22 | Grant/award | 72 | $15K |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | 2026-07-22 | L | 37 | $8K |
| Lassiter Wright III | Director | 2026-07-22 | L | 6 | $1K |
| MAIN TIMOTHY L | Director | 2026-07-22 | L | 21 | $4K |
| Plewman Patrick | SVP for Diagnostic Services | 2026-07-22 | L | 46 | $10K |
| SAMAD SAM | Executive Vice President & CFO | 2026-07-22 | Grant/award | 102 | $21K |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | 2026-06-04 | Option exercise 10b5-1 | 3320 | $424K |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | 2026-06-04 | Option exercise 10b5-1 | 4827 | $588K |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | 2026-06-04 | Open-market sell 10b5-1 | 8147 | $1.6M |
| Davis J. E. | CEO and President, Director | 2026-06-01 | Open-market sell 10b5-1 | 10000 | $1.9M |
| CARTER ROBERT B | Director | 2026-05-20 | Grant/award | 1142 | $0 |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
The FDA LDT regulatory overhang materially lifted following the March 2025 court vacatur, but three new risk vectors emerged that collectively offset the relief: tariff and trade-policy exposure now threatens supply chain costs and product availability, third-party consumer health partnerships introduce fresh data-handling and contractual liability, and M&A activity now carries added antitrust clearance and direct-to-consumer regulatory complexity. On balance, the risk profile shifted in multiple directions simultaneously, with the new exposures concentrated in operationally sensitive areas.
2 company-specific · 1 eased/removed · 1 common-mode
New disclosure of third-party health data handling risk via consumer health service partnerships, creating contractual and regulatory exposure not previously disclosed.
Our business operations and reputation may be materially impaired if we do not comply with privacy laws or information security policies. In our business, we collect, generate, process or maintain…
Added regulatory clearance/antitrust risk to M&A process; new disclosure of direct-to-consumer health services exposure with CLIA, corporate practice of medicine, and reimbursement risks.
Business development activities are inherently risky and integrating our operations with businesses we acquire may be difficult. We plan selectively to enhance our business from time to time through…
FDA LDT rule vacated by court in March 2025; FDA lost regulatory authority. Prior year described imminent four-year compliance burden; risk materially eased.
Our business and operations could be adversely impacted by the FDA's approach to regulation. The FDA has regulatory responsibility over, among other areas, instruments, software, test systems…
Added substantive disclosure of tariffs, sanctions, and trade policy risks with explicit impact on supply chain costs and product availability.
We are subject to numerous political (including geopolitical), legal, operational and other risks as a result of our international operations which could impact our business in many ways. Our…
Quest Diagnostics issued a press release on July 23, 2026 announcing second quarter 2026 financial results, including net revenues of $3.04 billion (up 10.2% YoY), diluted EPS of $2.84 (up 15.0% YoY), and adjusted diluted EPS of $3.12 (up 19.1% YoY). The company also raised full-year 2026 guidance for both revenues and EPS. This is a standard quarterly earnings release with detailed financial statements and forward guidance, clearly falling under Item 2.02 disclosure requirements.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure presenting the voting results from Quest Diagnostics' 2026 Annual Meeting of Stockholders held on May 20, 2026. The filing reports results for four distinct matters: election of 11 directors, advisory approval of executive compensation, ratification of PricewaterhouseCoopers as independent auditor, and a shareholder proposal on independent board chairman. All directors were elected with substantial majorities, compensation was approved, and the auditor was ratified, while the board chairman proposal failed. These results are material to investors assessing governance and board composition.
View raw filing on EDGAR →